NFGH
Nan Fung Group Holdings Portfolio holdings
AUM
$63.4M
This Quarter Return
+4.72%
1 Year Return
+35.61%
3 Year Return
+215.98%
5 Year Return
–
10 Year Return
–
AUM
$123M
AUM Growth
+$123M
(+4.9%)
Cap. Flow
+$11.6M
Cap. Flow
% of AUM
9.47%
Top 10 Holdings %
Top 10 Hldgs %
64.1%
Holding
36
New
1
Increased
9
Reduced
2
Closed
1
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$5.87M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$1.74M |
| 3 |
Oculis Holding
OCS
|
$1.49M |
| 4 |
argenx
ARGX
|
$1.4M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
$966K |
Top Sells
| 1 |
Rubrik
RBRK
|
$1.59M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$1.16M |
| 3 |
Incyte
INCY
|
$484K |
Sector Composition
| 1 | Healthcare | 99.8% |
| 2 | Materials | 0.2% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Harmony Biosciences
HRMY
$2.12B
| $12.2M | 9.98% |
368,665
| – | – |
|
|
2
Oculis Holding
OCS
$844M
| $9.79M | 7.99% |
514,702
+78,324
| +18% | +$1.49M |
|
3
Illumina
ILMN
$15.8B
| $9.46M | 7.71% |
119,196
| – | – |
|
|
VRNA
4
Verona Pharma
VRNA
$9.16B
| $9.4M | 7.66% |
147,990
+14,950
| +11% | +$949K |
|
5
Zai Lab
ZLAB
$3.68B
| $9.17M | 7.48% |
253,675
+18,675
| +8% | +$675K |
|
|
6
Mirum Pharmaceuticals
MIRM
$3.71B
| $6.61M | 5.39% |
146,765
+21,435
| +17% | +$966K |
|
|
7
Protagonist Therapeutics
PTGX
$3.67B
| $5.87M | 4.79% |
+121,400
| New | +$5.87M |
|
8
Soleno Therapeutics
SLNO
$3.6B
| $5.69M | 4.64% |
79,650
| – | – |
|
|
9
Xenon Pharmaceuticals
XENE
$2.98B
| $5.32M | 4.34% |
158,605
+51,925
| +49% | +$1.74M |
|
10
Merus
MRUS
$4.98B
| $5.05M | 4.12% |
120,038
| – | – |
|
|
ONC
11
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $4.28M | 3.49% |
15,722
-4,275
| -21% | -$1.16M |
|
12
Replimune Group
REPL
$422M
| $4.04M | 3.29% |
414,246
+92,500
| +29% | +$902K |
|
13
Madrigal Pharmaceuticals
MDGL
$9.76B
| $3.93M | 3.21% |
11,872
+750
| +7% | +$248K |
|
|
14
Incyte
INCY
$16.5B
| $3.57M | 2.91% |
59,022
-8,000
| -12% | -$484K |
|
15
Recursion Pharmaceuticals
RXRX
$2.04B
| $3.52M | 2.87% |
664,610
| – | – |
|
16
Tourmaline Bio
TRML
$601M
| $3.45M | 2.82% |
227,090
+40,000
| +21% | +$608K |
|
17
Rhythm Pharmaceuticals
RYTM
$6.85B
| $2.6M | 2.12% |
49,120
| – | – |
|
18
Exelixis
EXEL
$10.1B
| $2.37M | 1.93% |
64,200
| – | – |
|
19
Geron
GERN
$893M
| $2.18M | 1.78% |
1,373,550
| – | – |
|
20
Ascendis Pharma
ASND
$11.8B
| $2.12M | 1.73% |
13,600
| – | – |
|
21
Standard BioTools
LAB
$481M
| $2.03M | 1.66% |
1,883,179
| – | – |
|
22
KalVista Pharmaceuticals
KALV
$678M
| $1.78M | 1.45% |
154,522
| – | – |
|
23
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.71M | 1.4% |
102,984
| – | – |
|
|
24
argenx
ARGX
$43.6B
| $1.66M | 1.35% |
2,800
+2,370
| +551% | +$1.4M |
|
25
Kymera Therapeutics
KYMR
$2.95B
| $845K | 0.69% |
30,875
| – | – |
|